Cardiovascular Protective Effects of NP-6A4, a Drug with the FDA Designation for Pediatric Cardiomyopathy, in Female Rats with Obesity and Pre-Diabetes.

Anthony M Belenchia,Asma Boukhalfa,Vincent G DeMarco, Alexander Mehm,Abuzar Mahmood, Pei Liu,Yinian Tang,Madhavi P Gavini,Brian Mooney,Howard H Chen,Lakshmi Pulakat

Cells（2023）

引用 0|浏览5

暂无评分

摘要

Cardiac autophagy impairment underlies heart disease induced by obesity and pre-diabetes, and there are no drugs to re-activate autophagy. We propose that NP-6A4 can be an effective drug to reactivate cardiac autophagy and treat obesity- and pre-diabetes-induced heart disease, particularly for young and obese women.

查看译文

关键词

pediatric cardiomyopathy,obesity,fda designation,pre-diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要